Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

被引：0
|
作者：
Seoyoung C. Kim
Robert J. Glynn
Jun Liu
Brendan M. Everett
Allison B. Goldfine
机构：
[1] Brigham and Women’s Hospital,Division of Pharmacoepidemiology and Pharmacoeconomics
[2] Brigham and Women’s Hospital,Division of Rheumatology, Allergy and Immunology
[3] Brigham and Women’s Hospital,Division of Cardiovascular Medicine
[4] Joslin Diabetes Center,Clinical Research
来源：
Acta Diabetologica | 2014年 / 51卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Cardiovascular disease; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1015 / 1023
页数：8
相关论文
共 50 条
  • [31] Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
    Kaneko, Masayuki
    Narukawa, Mamoru
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 : 171 - 182
  • [32] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
    Papagianni, M.
    Tziomalos, K.
    HIPPOKRATIA, 2015, 19 (03) : 195 - 199
  • [33] Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
    Kim, Seoyoung C.
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Doherty, Michael
    Goldfine, Allison
    Solomon, Daniel H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1133 - S1133
  • [34] DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES
    Chen, W. S.
    Chang, Y. S.
    Tsai, C. Y.
    Chang, C. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1246 - 1247
  • [35] Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes
    Rouette, Julie
    Douros, Antonios
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB47 - AB47
  • [36] Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
    Davis, Timothy M. E.
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (08) : 450 - 451
  • [37] Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
    Baksh, Sheriza
    Wen, Jiajun
    Mansour, Omar
    Chang, Hsien-Yen
    McAdams-DeMarco, Mara
    Segal, Jodi B.
    Ehrhardt, Stephan
    Alexander, G. Caleb
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
  • [39] Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer among Patients with Type 2 Diabetes-Population-Based Cohort Study
    Pradhan, Richeek
    Azoulay, Laurent
    Platt, Robert W.
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
  • [40] Dipeptidyl peptidase-4 inhibitors and risk of diabetic retinopathy progression in patients with type 2 diabetes: a population-based cohort study
    Chung, Y. R.
    Ha, K. H.
    Kim, D. J.
    Lee, K.
    ACTA OPHTHALMOLOGICA, 2018, 96 : 23 - 23
12345